DarioHealth announced two new contracts to provide integrated chronic condition management solutions for two employers beginning in Q2. The employers, a national supply chain company and a regional education organization, selected Dario’s cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication. Employees enrolled in Dario’s cardiometabolic solution who are taking a GLP-1 medication will also have access to a tailored experience to support long-term behavior change.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth Raises CFO Zvi Ben-David’s Salary and Bonus Potential
- DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
- Is DRIO a Buy, Before Earnings?
- DarioHealth price target raised to $5.50 from $2.50 at Alliance Global Partners
- DarioHealth Corp Unveils Updated Investor Presentation